Spectrum Pharmaceuticals (SPPI) acquires Talon Therapeutics (TLON.OB), giving SPPI worldwide rights to the leukemia treatment Marqibo. Under the terms of the deal, SPPI will pay Talon's shareholders $11.3M in cash upfront and will issue 3M common shares in order to cancel outstanding debts under Talon's credit facility. Talon shareholders will also get CVRs potentially worth $195M depending upon sales of Marqibo and regulatory milestones for a Phase II product. SPPI (upgraded Tuesday by JMP) is +1.24% premarket.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.